These results suggest that VEGFCc156s treatment ameliorated angiotensin II-induced hypertension without altering angiotensin II infusion-mediated aortic stiffness and the subsequent renal compensatory response, elucidating another mechanism underlying the beneficial effects of VEGFCc156s on angiotensin II-induced cardiac dysfunction. Here, AGT is linked to Hypertension.